ArticleCureus2025
Expression of Alanine-Serine-Cysteine Transporter 2 (ASCT2) and L-type Amino Acid Transporter 1 (LAT1) in Low-Grade and High-Grade Gliomas: An Analysis of Open-Access Immunohistochemical Data.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe amino acid transporters alanine-serine-cysteine transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) are the primary transporters of essential amino acids in cancer. ASCT2 and LAT1 are overexpressed in solid tumors and have been associated with poor survival. These transporters may hold prognostic significance and offer potential theranostic utility in the treatment of glioma. The aims of this study are twofold: (1) to determine whether ASCT2 and LAT1 mRNA expression are related to glioma grade and survival; and (2) to characterize ASCT2 and LAT1 expression in low-grade glioma (LGG) and high-grade glioma (HGG).
methodsSurvival and mRNA expression data for both ASCT2 and LAT1 were obtained from The Cancer Genome Atlas (TCGA), accessed via the cBio Cancer Genomics Portal. GraphPad Prism was used to conduct a Kaplan-Meier survival analysis. Immunohistochemistry images were obtained from the Human Protein Atlas (HPA) database and analyzed with QuPath for ASCT2 and LAT1 expression in the cytoplasm and at the endothelium.
resultsQuery of TCGA resulted in 49 samples from 28 patients, which were evaluated for ASCT2 and LAT1 expression. Cytoplasmic staining of mRNA for ASCT2 and LAT1 was not associated with glioma grade or survival. Higher mRNA expression of ASCT2 correlated with worse survival (p=0.002) in LGG but not in HGG. mRNA expression of LAT1 did not have any prognostic value. QuPath analysis of samples from the HPA showed increased staining for both ASCT2 and LAT1 at the endothelium in both LGG and HGG. Endothelial expression of ASCT2 and LAT1 correlated with glioma grade.
conclusionIn our small study conducted with open-access data, ASCT2 and LAT1 did not appear to have prognostic value. However, both ASCT2 and LAT1 staining were increased at the endothelium compared to normal brain tissue. These amino acid transporters may play an important role in tumor proliferation and support theranostic approaches to glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.